Skip to main content

Drug Interactions between Mono-Linyah and pentoxifylline

This report displays the potential drug interactions for the following 2 drugs:

Edit list (add/remove drugs)

Interactions between your drugs

Moderate

ethinyl estradiol pentoxifylline

Applies to: Mono-Linyah (ethinyl estradiol / norgestimate) and pentoxifylline

Consumer information for this interaction is not currently available.

MONITOR: Coadministration with inhibitors of CYP450 1A2 may increase the plasma concentrations of pentoxifylline and its active hydroxy metabolite (M1), both of which are substrates of the isoenzyme. In a study consisting of eight healthy, nonsmoking volunteers, mean pentoxifylline systemic exposure (AUC) increased by approximately 35% when pentoxifylline 300 mg was administered intravenously one hour after a single 750 mg oral dose of ciprofloxacin, a moderate CYP450 1A2 inhibitor. The R- and S-enantiomers of the M1 metabolite also increased by 39% and 37%, respectively.

MANAGEMENT: Pharmacologic response to pentoxifylline should be monitored more closely whenever a potent or moderate CYP450 1A2 inhibitor is added to or withdrawn from therapy, and the pentoxifylline dosage adjusted as necessary. Patients should be advised to seek medical attention if they experience serious adverse effects such as bleeding, angina, or arrhythmias.

Drug and food interactions

Moderate

norgestimate food

Applies to: Mono-Linyah (ethinyl estradiol / norgestimate)

Grapefruit juice may increase the blood levels of certain medications such as norgestimate. You may want to limit your consumption of grapefruit and grapefruit juice during treatment with norgestimate. However, if you have been regularly consuming grapefruit or grapefruit juice with the medication, then it is advisable for you to talk with your doctor before changing the amounts of these products in your diet, as this may alter the effects of your medication. Contact your doctor if your condition changes or you experience increased side effects. Orange juice is not expected to interact.

Moderate

ethinyl estradiol food

Applies to: Mono-Linyah (ethinyl estradiol / norgestimate)

Consumer information for this interaction is not currently available.

MONITOR: Coadministration of ethinyl estradiol may increase the plasma concentrations of drugs that are primarily metabolized by CYP450 1A2. In a study of 30 healthy volunteers administered the CYP450 1A2 substrate tizanidine, the systemic exposure (AUC) of tizanidine was 3.9 times greater in women using an oral contraceptive containing ethinyl estradiol.

MANAGEMENT: Patients should be monitored for increased adverse effects of the CYP450 1A2 substrate during concomitant use with ethinyl estradiol. Product labeling for the specific CYP450 1A2 substrate should be consulted for additional recommendations.

Minor

ethinyl estradiol food

Applies to: Mono-Linyah (ethinyl estradiol / norgestimate)

Information for this minor interaction is available on the professional version.

Minor

ethinyl estradiol food

Applies to: Mono-Linyah (ethinyl estradiol / norgestimate)

Information for this minor interaction is available on the professional version.

Therapeutic duplication warnings

No warnings were found for your selected drugs.

Therapeutic duplication warnings are only returned when drugs within the same group exceed the recommended therapeutic duplication maximum.

See also

Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer